Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ono Pharmaceutical
Pharma
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.
Angus Liu
Feb 14, 2025 6:24pm
AstraZeneca-CSPC, Astellas and more—Fierce Pharma Asia
Oct 11, 2024 9:48am
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
May 3, 2024 7:20am
Opdivo maker Ono pays $2.4B for Deciphera
Apr 29, 2024 8:55am
Takeda, WuXi, LianBio—Fierce Pharma Asia
Feb 16, 2024 8:24am
FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia
Apr 1, 2022 9:35am